01—Abstract
Summary
Summary of the 8-K filed May 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. (NYSE: ZTS) filed this 8-K to report governance changes and the results of its May 21, 2025 Annual Meeting of Shareholders.
Robert Scully retired from the Board effective May 21, 2025, under the company's director retirement policy, and Dr. Mark Stetter, Dean of the University of California, Davis School of Veterinary Medicine, was elected to the Board at the meeting. He will serve on the Quality and Innovation Committee. The filing contains no financial results, guidance, or operating metrics.
Its investor relevance is governance and shareholder sentiment. Shareholders approved all three company-backed proposals. Holders representing 88.08%a of eligible voting power attended, well above the quorum requirement.
All twelve director nominees were re-elected to one-year terms, and the non-binding say-on-pay advisory vote passed, with roughly 90%b of votes cast in favor (334.2 million for vs. 35.2 million against). KPMG LLP was ratified as the independent auditor for fiscal 2025. The one shareholder proposal on special shareholder meetings failed decisively, with about 86% of votes cast against (320.7 million against vs. 50.4 million for).
The results point to broadly strong shareholder support for management and the Board. Director support was generally high, although Gregory Norden (about 93%c for), Michael McCallister (about 96%), and Frank D'Amelio (about 94%) drew the largest against-vote totals among the nominees. The defeat of the special-meeting proposal suggests shareholders did not want to change the company's current governance terms on that issue.
02—Key points
Key Highlights
- Robert Scully retired from the Board effective May 21, 2025, under the company's director retirement policy, ahead of the Annual Meeting.
- Dr. Mark Stetter, a veterinarian and Dean of UC Davis School of Veterinary Medicine, was elected to the Board effective May 21, 2025, and will sit on the Quality and Innovation Committee.
- All twelve director nominees were elected to one-year terms, with Mark Stetter receiving the strongest support (about 99% for) and Gregory Norden the weakest (about 93% for).
- The non-binding say-on-pay vote passed, with about 90% of votes cast in favor (334.2M for vs. 35.2M against).
- Shareholders ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2025 (384.8M for vs. 7.6M against).
- The shareholder proposal on a special shareholder meeting improvement failed, with about 86% of votes cast against (320.7M against vs. 50.4M for).
- Quorum was met with 392.9M shares, or 88.08% of voting power, present in person or by proxy.
03—Questions
Frequently Asked Questions
Does this filing include any financial results or guidance?
No. The 8-K covers only board changes and Annual Meeting voting results (Items 5.02 and 5.07), plus a press release on Dr. Stetter's election. It contains no revenue, earnings, or guidance information. The only financial figure is the 2024 revenue of $9.3 billion, which appears in the press release boilerplate.
Who is Dr. Mark Stetter and why is his appointment relevant?
Dr. Stetter has served as Dean of UC Davis School of Veterinary Medicine since 2021 and previously was Dean at Colorado State University's College of Veterinary Medicine and Biomedical Sciences. He also held roles at The Walt Disney Company, the Bronx Zoo/Wildlife Conservation Society, and the Audubon Nature Institute. The company describes his added value as hands-on animal health expertise, and his placement on the Quality and Innovation Committee suggests a role in product and innovation oversight.
Did shareholders support management's compensation plan?
Yes. The non-binding say-on-pay advisory vote passed, with about 334.2 million votes for and 35.2 million against, or roughly 90% support among votes cast. Because the vote is advisory, it does not bind the Board, but the level of support indicates broad shareholder approval of the named executive officer pay program as disclosed in the proxy statement.
Why did the special shareholder meeting proposal fail, and does that matter for investors?
Shareholders voted against the proposal by about 320.7 million to 50.4 million, so it did not pass. The filing does not say why shareholders rejected it, and the proposal's full text is in the proxy statement. The result suggests shareholders did not favor changing the current special meeting provisions. Investors who prioritized shareholder access to special meetings may view this as a governance point to monitor.
Were there any notable concerns in the director vote?
Support was high across all nominees, but several received more against-votes than others. Gregory Norden drew about 24.9 million against votes (about 93% support), Michael McCallister about 16.3 million (about 96%), and Frank D'Amelio about 20.6 million (about 94%). Broker non-votes of about 20.8 million applied to each director nominee, which is typical for uninstructed shares and does not indicate opposition.
04—Continue